RET inhibition: implications in cancer therapy

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert opinion on therapeutic targets

• Publication date

  2013-03-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14728222.2013.758715PMID 23461584
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intracellular Signal Transduction and Modification of the Tumor Microenvironment Induced by RET/PTCs in Papillary Thyroid Carcinoma

  2012cited by this paper
• The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells

  2012cited by this paper
• Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

  2012influential reference
• Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series

  2012cited by this paper
• RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation

  2012cited by this paper
• Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

  2012cited by this paper
• Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

  2012cited by this paper
• KIF5B-RET fusions in lung adenocarcinoma

  2012influential reference
• MRG-1 is required for genomic integrity in Caenorhabditis elegans germ cells

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• The transcriptional landscape and mutational profile of lung adenocarcinoma

  2012cited by this paper
• Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).

  2012cited by this paper
• RET, ROS1 and ALK fusions in lung cancer

  2012influential reference
• Low Prevalence of the Somatic M918T RET Mutation in Micro-Medullary Thyroid Cancer

  2012cited by this paper
• An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.

  2012cited by this paper
• Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

  2012cited by this paper
• A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.

  2012influential reference
• Completing the Arc: targeted inhibition of RET in medullary thyroid cancer.

  2012cited by this paper
• RET in breast cancer: functional and therapeutic implications.

  2011cited by this paper
• A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC).

  2011cited by this paper
• Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

  2011cited by this paper
• Focal Adhesion Kinase (FAK) Binds RET Kinase via Its FERM Domain, Priming a Direct and Reciprocal RET-FAK Transactivation Mechanism*

  2011cited by this paper
• New driver mutations in non-small-cell lung cancer.

  2011cited by this paper
• Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation

  2011cited by this paper
• Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

  2011influential reference
• Anti-tumor activity of motesanib in a medullary thyroid cancer model

  2011cited by this paper
• ALK Inhibitors, a Pharmaceutical Perspective

  2011cited by this paper
• Development of RET kinase inhibitors for targeted cancer therapy.

  2011cited by this paper
• Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

  2011influential reference
• High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

  2011cited by this paper
• Phase II trial of sunitinib in medullary thyroid cancer (MTC).

  2010cited by this paper
• Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC.

  2010cited by this paper
• Cancer facts and figures

  2010cited by this paper
• Clinical Cancer esearch cer Therapy : Clinical se II Study of Daily Sunitinib in FDG-PET – Positive , ne-Refractory Differentiated Thyroid Cancer and astatic Medullary Carcinoma of the Thyroid R Functional Imaging Correlation

  2010cited by this paper
• Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance

  2010cited by this paper
• Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

  2010cited by this paper
• Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.

  2010cited by this paper
• Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

  2010cited by this paper
• [18F]Fluorodeoxyglucose positron emission tomography in the initial staging of squamous cell carcinoma of the head and neck: promise, evidence, and reality.

  2010cited by this paper
• XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.

  2010cited by this paper
• Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.

  2009cited by this paper
• Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.

  2009cited by this paper
• RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation.

  2009cited by this paper
• Functional RET G691S Polymorphism in Cutaneous Malignant Melanoma

  2009cited by this paper
• Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST).

  2009cited by this paper
• Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent Advances

  2009cited by this paper
• Molecular pathology of differentiated thyroid cancer.

  2009influential reference
• Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

  2009cited by this paper
• Multiple endocrine neoplasia type 2 RET protooncogene database: Repository of MEN2‐associated RET sequence variation and reference for genotype/phenotype correlations

  2009cited by this paper
• Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

  2009cited by this paper
• Phase 2 study of sunitinib in refractory thyroid cancer

  2008cited by this paper
• First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

  2008influential reference
• High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma.

  2008cited by this paper
• Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

  2008cited by this paper
• Phase II trial of sorafenib in advanced thyroid cancer.

  2008influential reference
• Sixty years of follow-up of Hiroshima and Nagasaki survivors: current progress in molecular epidemiology studies.

  2008cited by this paper
• Motesanib diphosphate in progressive differentiated thyroid cancer.

  2008cited by this paper
• Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and 4-substituted beta-carbolin-1-ones.

  2008cited by this paper
• The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.

  2007cited by this paper
• Sunitinib: from rational design to clinical efficacy.

  2007cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2007cited by this paper
• Sorafenib Functions to Potently Suppress RET Tyrosine Kinase Activity by Direct Enzymatic Inhibition and Promoting RET Lysosomal Degradation Independent of Proteasomal Targeting*

  2007cited by this paper
• Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

  2007influential reference
• RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.

  2006influential reference
• Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity.

  2006cited by this paper
• Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain*

  2006cited by this paper
• An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

  2006cited by this paper
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

  2006influential reference
• Radiation-induced thyroid cancer: What we have learned from Chernobyl

  2006cited by this paper
• AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.

  2006cited by this paper
• Activation of the Erk8 Mitogen-activated Protein (MAP) Kinase by RET/PTC3, a Constitutively Active Form of the RET Proto-oncogene*

  2006cited by this paper
• Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

  2006cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2006cited by this paper
• BAY 43-9006 inhibition of oncogenic RET mutants.

  2006cited by this paper
• The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.

  2005cited by this paper
• RET tyrosine kinase signaling in development and cancer.

  2005influential reference
• Molecular genetics of multiple endocrine neoplasia types 1 and 2

  2005influential reference
• Distinct Turnover of Alternatively Spliced Isoforms of the RET Kinase Receptor Mediated by Differential Recruitment of the Cbl Ubiquitin Ligase*

  2005cited by this paper
• Biology of desmoplastic melanoma: a case-control comparison with other melanomas.

  2005cited by this paper
• Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.

  2005cited by this paper
• Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.

  2004cited by this paper
• Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

  2004cited by this paper
• Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branching

  2004cited by this paper
• Biochemical and biological responses induced by coupling of Gab1 to phosphatidylinositol 3-kinase in RET-expressing cells.

  2004cited by this paper
• The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells

  2004cited by this paper
• Identification of RET Autophosphorylation Sites by Mass Spectrometry*

  2004cited by this paper
• Dysfunction of the RET receptor in human cancer.

  2004cited by this paper
• PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting.

  2003cited by this paper
• Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma.

  2003cited by this paper
• Differential interaction of Enigma protein with the two RET isoforms.

  2002cited by this paper
• The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes.

  2002cited by this paper
• The Protein Kinase Complement of the Human Genome

  2002cited by this paper
• ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

  2002cited by this paper
• Coordinated Activation of Autophosphorylation Sites in the RET Receptor Tyrosine Kinase

  2002cited by this paper
• ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

  2002cited by this paper
• World Health Organization Classification of Tumours

  2002cited by this paper
• The Long and Short Isoforms of Ret Function as Independent Signaling Complexes*

  2002cited by this paper
• Conservation of RET proto-oncogene splicing variants and implications for RET isoform function

  2002cited by this paper
• The clinical behavior of desmoplastic melanoma.

  2001cited by this paper
• Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor

  2000cited by this paper

• Inhibitory Effects of Vandetanib on Catecholamine Synthesis in Rat Pheochromocytoma PC12 Cells

  2025cites this paper
• Investigating Drug-Induced Thyroid Dysfunction Adverse Events Associated With Non-Selective RET Multi-Kinase Inhibitors: A Pharmacovigilance Analysis Utilizing FDA Adverse Event Reporting System Data

  2025cites this paper
• Design and Synthesis of Novel Thieno[3,2-c]quinoline Compounds with Antiproliferative Activity on RET-Dependent Medullary Thyroid Cancer Cells

  2023cites this paper
• Deciphering the resistance mechanism of RET kinase mutant against vandetanib and nintedanib using molecular dynamics simulations

  2021cites this paper
• Discovery of a Potent Candidate for RET-Specific Non-Small-Cell Lung Cancer—A Combined In Silico and In Vitro Strategy

  2021cites this paper
• Discovery and Optimization of Selective RET Inhibitors via Scaffold Hopping.

  2021cites this paper
• Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?

  2020cites this paper
• Recent developments of RET protein kinase inhibitors with diverse scaffolds as hinge binders.

  2020cites this paper
• CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target

  2019cites this paper
• RET fusion in advanced non-small-cell lung cancer and response to cabozantinib

  2019cites this paper
• RET in breast cancer: pathogenic implications and mechanisms of drug resistance

  2019cites this paper
• Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity

  2018cites this paper
• Pharmacological Augmentation of Heavy Ion Cancer Therapy

  2018cites this paper
• Novel targeted therapeutics for MEN2.

  2018cites this paper
• Evaluation of RET Gene Rearrangement by Fluorescence In Situ Hybridization in Malignant Mesothelioma.

  2018cites this paper
• The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer

  2018cites this paper
• Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.

  2018cites this paper
• Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer

  2017cites this paper
• RET kinase inhibitors: a review of recent patents (2012–2015)

  2017cites this paper
• Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors

  2017cites this paper
• in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy.

  2016cites this paper
• Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET kinase inhibitors.

  2016cites this paper
• Évaluation d'une nouvelle technique de biologie moléculaire, la LD-RTPCR, pour la recherche de réarrangement des gènes ALK, ROS et RET dans l'adénocarcinome pulmonaire

  2016cites this paper
• Drosophila Cancer Models Identify Functional Differences between Ret Fusions.

  2016cites this paper
• Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy

  2016cites this paper
• Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway

  2016cites this paper
• An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma

  2015cites this paper
• Correlation analysis of ultrasonic characteristics, pathological type, and molecular markers of thyroid nodules.

  2015cites this paper
• The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis

  2015cites this paper
• Germ-line variants identified by next generation sequencing in a panel of estrogen and cancer associated genes correlate with poor clinical outcome in Lynch syndrome patients

  2015cites this paper
• The anti-hypertensive drug prazosin induces apoptosis in the medullary thyroid carcinoma cell line TT.

  2015influential citation
• The histone code reader SPIN1 controls RET signaling in liposarcoma

  2015cites this paper
• Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor

  2014cites this paper
• New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.

  2014cites this paper
• Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.

  2014cites this paper
• Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC

  2014cites this paper
• Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86

  2014influential citation
• Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.

  2014cites this paper
• RET revisited: expanding the oncogenic portfolio

  2014cites this paper
• Recent advances in personalized lung cancer medicine.

  2014cites this paper
• RET fusion gene: Translation to personalized lung cancer therapy

  2013cites this paper
• Kinase Inhibitors in Cancer

  2013cites this paper
• Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.

  2013influential citation